Skip to main content
Douglas Blayney, MD, Oncology, Stanford, CA

DouglasWBlayneyMD

Oncology • Stanford, CA

Breast Cancer, Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Blayney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Blayney's full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Stanford, CA 94305
    Phone+1 650-723-4000
    Fax+1 650-498-5840

Education & Training

  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterResidency, Internal Medicine, 1977 - 1980
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 1977

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1978 - 2026
  • MI State Medical License
    MI State Medical License 2003 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Fellow (FASCO) American Society of Clinical Oncologists, 2007

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non–Small Cell Lung Cancer  
    Douglas W Blayney, Santosh Nair, JAMA Oncology

Lectures

  • Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and... 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination. 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
  • A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphami... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • How Do Cancer Biosimilars Stack up Against the Original Products?
    How Do Cancer Biosimilars Stack up Against the Original Products?February 4th, 2022
  • ‘American Ninja Warrior’ Contestant Overcame Cancer but Still Suffers from Memory Loss; Exercise Can Reduce Chemo Brain
    ‘American Ninja Warrior’ Contestant Overcame Cancer but Still Suffers from Memory Loss; Exercise Can Reduce Chemo BrainSeptember 28th, 2021
  • BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
    BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual MeetingJune 7th, 2021
  • Join now to see all

Professional Memberships

Dr. Douglas Blayney, Dr. Douglas Blayney, MD, Dr. D Blayney, Dr. Douglas W Blayney